Muhammad W. Sadiq
R&d
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial.
Journal: The Journal of allergy and clinical immunology
Published: November 28, 2025
FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.
Journal: ERJ open research
Published: February 07, 2025
Assessing Human Lung Pharmacokinetics Using Exhaled Breath Particles.
Journal: Journal of aerosol medicine and pulmonary drug delivery
Published: December 05, 2024
A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.
Journal: The European respiratory journal
Published: November 08, 2024
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery.
Journal: CPT: pharmacometrics & systems pharmacology
Published: July 29, 2024
Efficacy and safety of tozorakimab in moderate-to-severe atopic dermatitis: A Phase 2a randomized controlled trial (FRONTIER-2).
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 20, 2024
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease.
Journal: British journal of clinical pharmacology
Published: December 04, 2023
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants.
Journal: Clinical pharmacology in drug development
Published: October 31, 2023
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease.
Journal: Clinical pharmacology and therapeutics
Published: August 15, 2023
Possible Extraction of Drugs from Lung Tissue During Broncho-alveolar Lavage Suggest Uncertainty in the Procedure's Utility for Quantitative Assessment of Airway Drug Exposure.
Journal: Journal of pharmaceutical sciences
Published: August 25, 2021
Diurnal variation in DLCO and non-standardized study procedures may cause a false positive safety signal in clinical trials.
Journal: Respiratory medicine
Published: July 13, 2021
Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease.
Journal: British journal of clinical pharmacology
Published: January 21, 2021
Last Updated: 09/26/2026